Suganuma Masami, Kurusu Miki, Suzuki Kaori, Tasaki Emi, Fujiki Hirota
Research Institute of Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
Int J Cancer. 2006 Jul 1;119(1):33-40. doi: 10.1002/ijc.21809.
To more clearly understand the molecular mechanisms involved in synergistic enhancement of cancer preventive activity with the green tea polyphenol (-)-epigallocatechin gallate (EGCG), we examined the effects of cotreatment with EGCG plus celecoxib, a cyclooxygenase-2 selective inhibitor. We specifically looked for induction of apoptosis and expression of apoptosis related genes, with emphasis on growth arrest and DNA damage-inducible 153 (GADD153) gene, in human lung cancer cell line PC-9: Cotreatment with EGCG plus celecoxib strongly induced the expression of both GADD153 mRNA level and protein in PC-9 cells, while neither EGCG nor celecoxib alone did. However, cotreatment did not induce expression of other apoptosis related genes, p21(WAF1) and GADD45. Judging by upregulation of GADD153, only cotreatment with EGCG plus celecoxib synergistically induced apoptosis of PC-9 cells. Synergistic effects with the combination were also observed in 2 other lung cancer cell lines, A549 and ChaGo K-1. Furthermore, EGCG did not enhance GADD153 gene expression or apoptosis induction in PC-9 cells in combination with N-(4-hydroxyphenyl)retinamide or with aspirin. Thus, upregulation of GADD153 is closely correlated with synergistic enhancement of apoptosis with EGCG. Cotreatment also activated the mitogen-activated protein kinases (MAPKs), such as ERK1/2 and p38 MAPK: Preteatment with PD98059 (ERK1/2 inhibitor) and UO126 (selective MEK inhibitor) abrogated both upregulation of GADD153 and synergistic induction of apoptosis of PC-9 cells, while SB203580 (p38 MAPK inhibitor) did not do so, indicating that GADD153 expression was mediated through the ERK signaling pathway. These findings indicate that high upregulation of GADD153 is a key requirement for cancer prevention in combination with EGCG.
为了更清楚地了解绿茶多酚(-)-表没食子儿茶素没食子酸酯(EGCG)协同增强癌症预防活性所涉及的分子机制,我们研究了EGCG与环氧化酶-2选择性抑制剂塞来昔布联合处理的效果。我们特别研究了人肺癌细胞系PC-9中细胞凋亡的诱导以及凋亡相关基因的表达,重点关注生长停滞和DNA损伤诱导蛋白153(GADD153)基因:EGCG与塞来昔布联合处理强烈诱导了PC-9细胞中GADD153 mRNA水平和蛋白的表达,而单独使用EGCG或塞来昔布均未诱导。然而,联合处理并未诱导其他凋亡相关基因p21(WAF1)和GADD45的表达。从GADD153的上调情况判断,只有EGCG与塞来昔布联合处理能协同诱导PC-9细胞凋亡。在另外两种肺癌细胞系A549和ChaGo K-1中也观察到了联合用药的协同效应。此外,EGCG与N-(4-羟基苯基)视黄酸或阿司匹林联合使用时,并未增强PC-9细胞中GADD153基因的表达或诱导细胞凋亡。因此,GADD153的上调与EGCG协同增强细胞凋亡密切相关。联合处理还激活了丝裂原活化蛋白激酶(MAPK),如ERK1/2和p38 MAPK:用PD98059(ERK1/2抑制剂)和UO126(选择性MEK抑制剂)预处理可消除PC-9细胞中GADD153的上调和凋亡的协同诱导,而SB203580(p38 MAPK抑制剂)则无此作用,表明GADD153的表达是通过ERK信号通路介导的。这些发现表明,GADD153的高度上调是与EGCG联合预防癌症的关键要求。